Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma

Patients with haematological malignancies are considered to be a risk group for developing severe Coronavirus disease (Covid-19). Because of the limitations of therapeutic options, the development of new treatment strategies is mandatory, such as convalescent plasma (CP). Herein we report the use of CP therapy as an off-label indication in two lymphoma patients with relapsed COVID-19 in the setting of low gammaglobulin levels because of previous rituximab chemo-immunotherapy. Both were PCR positive for SARS-CoV-2 but had an absence of antibodies to the virus more than one month later of symptoms initiation.

Source: Transfusion and Apheresis Science - February 19, 2021 Category: Hematology Authors: Irati Ormazabal V élez, Juan Induráin Bermejo, José Espinoza Pérez, Laura Imaz Aguayo, Marina Delgado Ruiz, José Antonio García-Erce Source Type: research